The Endocannabinoid Activity Remodulation for psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis

Author:

Bortoletto Riccardo1ORCID,Garzitto Marco1,Piscitelli Fabiana2,Comacchio Carla3,Curcio Francesco1,Fabris Martina3,Sepulcri Orietta3,Balestrieri Matteo1,Colizzi Marco1

Affiliation:

1. University of Udine: Universita degli Studi di Udine

2. National Research Council: Consiglio Nazionale delle Ricerche

3. Azienda Sanitaria Universitaria Integrata di Udine: Azienda sanitaria universitaria Friuli Centrale

Abstract

Abstract Background To date, no psychotropic medication has shown to effectively halt progression to psychosis among individuals at Clinical High-Risk for psychosis (CHR), fueling the search for novel therapeutic agents. Recent evidence supports Palmitoylethanolamide (PEA) signaling as a potential psychosis biomarker, also indicating a therapeutic role for its supplementation. Nonetheless, the effect of sustained PEA intake in CHR subjects has never been explored so far. Methods We will assess the feasibility of enrolling 20 CHR young adults presenting with attenuated psychotic symptoms (APS) in a 12-week, open-label, investigator-initiated, proof-of-concept, single-arm trial of PEA 600 mg/day. Once completed the 12-week phase, participants will be proposed to enter a 24-week extension phase of the study. We will examine PEA ability to reduce APS and psychic distress, PEA safety and tolerability, and the biological basis of PEA effect in terms of modulation of inflammatory response, endocannabinoid (eCB) system, and microbiome. Discussion Our trial aims to address an unmet clinical need in CHR subjects, providing an initial solid basis for the development of future studies evaluating the efficacy and tolerability of PEA supplementation in this group of patients. Trial registration Clinicaltrials.gov, NCT06037993 (https://classic.clinicaltrials.gov/ct2/show/NCT06037993). Registered on 21 September 2023. Retrospectively registered.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3